Category: 98488-99-4

Lee, T. B.; Swan, G. A. published an article in 1956, the title of the article was The constitution of yohimbine and related alkaloids. IX. Synthesis of 2-(4,5-diethyl-2-pyridyl)-3-ethylindole (alstyrine or coryline) and two related compounds.Recommanded Product: 98488-99-4 And the article contains the following content:

cf. C.A. 49, 12496a. Synthetic 2-(4,5-diethyl-2-pyridyl)-3-ethylindole and 4,5-diethylpyridine-2-carboxylic acid were identical with the appropriate degradation products of the Alstonia alkaloids and of corynantheine. Synthetic 3-ethyl-2-(5-ethyl-2-pyridyl)-5-methoxyindole did not appear to be identical with the degradation product from aricine. The 4-ethyl derivative of this was also synthesized. Adding 54 cc. 30% H2O2 to 86 g. 5-ethyl-2-methylpyridine in 250 cc. HOAc, after 5 hrs. at 70°, adding 40 cc. 30% H2O2 and keeping at 70-80° 15 hrs. gave a solution which on concentration in vacuo to 100 cc., addition of 100 cc. H2O and evaporation almost to dryness gave a residue which on basification (Na2CO3) and CHCl3 extraction afforded 52 g. 5-ethyl-2-methylpyridine N-oxide (I), b2 124-8°; picrate, m. 107-8°. Dropwise addition of a solution of 52 g. I in 98 cc. H2SO4 to a stirred mixture of 156 cc. H2SO4 and 175 cc. HNO3 (d. 1.2) at room temperature, followed by heating to 90-100° 3 hrs., cooling, and adding dropwise to stirred ice-NH4OH (d. 0.880) yielded 48 g. 5-ethyl-2-methyl-4-nitropyridine N-oxide, m. 80°. A solution of 10 g. of this in 50 cc. C6H6 on dropwise addition of 50 cc. PBr3 followed by refluxing 7 hrs. on a 125-40° bath gave a product which poured on ice, followed by basification (10% NaOH) and CHCl3 extraction gave 6.6 g. 4-bromo-5-ethyl-2-methylpyridine (II), b20 105-10°; picrate, m. 141-2° (decomposition); methiodide, m. 167-9°. Addition to a solution of 20 g. CuCN and 46 g. KCN in 180 cc. H2O of 28 g. II in 120 cc. EtOH followed by heating (autoclave, 180-200°, 4 hrs.), adjustment (concentrated HCl) to pH 4, removal of CuCN, evaporation to dryness, and drying by evaporation 3 times with EtOH gave a solid which on solution in 100 cc. EtOH, saturation with dry HCl, keeping overnight followed by 4 hrs. refluxing, removal of EtOH, basification and extraction afforded 12.15 g. Et 5-ethyl-2-methylpyridine-4-carboxylate (III), b2 112-15°; picrate, m. 129-30° (Berson and Cohen, C.A. 50, 9405i). Hydrolysis (20% KOH, reflux 90 min.) of III followed by adjustment to pH 4 gave by Et2O extraction the free acid, m. 226-8°, after purification by sublimation (140°/0.1 mm.). Addition of 12.5 g. III and 32 cc. EtOAc to KOEt (from 6.3 g. K) in C6H6 followed by 12 hrs. refluxing and addition of 140 cc. H2O gave a solution which after Et2O washing (to remove uncondensed ester), addition of 280 cc. concentrated HCl, heating overnight on a water-bath, evaporation to dryness, basification and Et2O extraction yielded 7.3 g. 4-acetyl-5-ethyl-2-methylpyridine (IV), b20 114-18°; picrate, m. 132-4°; oxime, m. 107°. Clemmensen reduction of 7.3 g. IV gave 4.3 g. 4,5-diethyl-2-methylpyridine (V), prepared by Kao and Robinson (C.A. 50, 5620b); styphnate, m. 155-6°. The residue from the working up contained 5-ethyl-4-(1-hydroxyethyl)-2-methylpyridine, b0.1 100-5° (picrate, m. 137-9°); reduction (HIP) of this base gave V. On refluxing 70 hrs. 4.3 g. V with 11 cc. BzH and 11 cc. Ac2O in 12 cc. xylene followed by acidification (17% HCl to Congo red), removal (steam distillation) of BzH, basification (NaOH), and CHCl3 extraction gave 1 g. unchanged V and 4.3 g. 4,5-diethyl-2-styrylpyridine (VI), picrate, m. 241-3° (decompose) (cf. K. and R., loc. cit.). Oxidation of 2 g. VI in Me2CO at 0° by the addition of 7 g. KMnO4 followed by 1 hr. stirring, removal and washing (Me2CO and H2O) of MnO2, and extraction of BzOH, gave on continuous Et2O extraction of the aqueous liquor at pH 4 0.6 g. 4,5-diethylpyridine-2-carboxylic acid (VII), m. 147-8°, λmaximum 2680 and 2300 A. (log ε 3.61 and 3.90 resp.), λmin. 2520 A. (log. ε 3.44), identical by mixed m.p. with acid of natural origin. Demethylation (Cu powder) of VII gave 4,5-diethylpyridine, identified as the picrate. VII (0.6 g.) on esterification (10 cc. EtOH and dry HCl at 0°, standing overnight and then refluxing for 2 hrs.) gave 0.6 g. Et ester (VIII), b3 140-5°; picrate, m. 88-90°. VIII (0.5 g.) with 5 cc. NH4OH (d. 0.880) 48 hrs. (room temperature) followed by 2 hrs. stirring yielded 2-carbamoyl-4,5-diethylpyridine (VIIIa), subliming at 100-20°/0.1 mm., m. 177-8°. Dehydration (1 cc. POCl3, reflux 2 hrs.) of 0.4 g. VIIIa gave on working up 0.2 g. 2-cyano-4,5-diethylpyridine, b20 150-60°, which (1.3 g.) in 75 cc. EtOH added with stirring to PrMgBr (from 0.6 g. Mg and 2.7 g. PrBr in 15 cc. Et2O), and the mixture refluxed 3 hrs. and decomposed (30 cc. saturated NH4Cl and 5 cc. concentrated HCl) afforded on basification and Et2O extraction 1.2 g. 2-butyryl-4,5-diethylpyridine (IX), b3 142-6°; picrate, m. 97-8°; phenylhydrazone picrate, m. 211-12°; p-methoxyphenylhydrazone picrate, m. 160-1°. On heating 0.334 g. IX with 0.18 g. PhNHNH2 in vacuo on a steam bath 2 hrs., the product, on solution in 20 cc. EtOH, cooling in ice, keeping at room temperature 1 hr. followed by refluxing 2 hrs., gave on evaporation, basification, and Et2O extraction 0.3 g. 2-(4,5-diethyl-2-pyridyl)-3-ethylindole (X), b0.4 200-10°, m. 110-1°, identical by mixed m.p. with alstyrine from alkaloidal degradation, λmaximum 3250 A. (log ε 4.36), and λmin. 2740 A. log ε 3.63; picrate, m. 218-21°; hydrochloride, softened at 190° and melted completely at 203°. As in the synthesis from VI above, starting from 4 g. ethyl 5-ethylpyridine-2-carboxylate there were obtained: 3 g. 2-carbamoyl-5-ethylpyridine, m. 147-8°; 1.7 g. 2-cyano-5-ethylpyridine, b20 132°; 1.3 g. 2-butyryl-5-ethylpyridine (XI) (p-methoxyphenylhydrazone picrate, m. 176-7°). XI with p-MeOC6H4NHNH2 yielded 3-ethyl-2-(5-ethyl-2-pyridyl)-5-methoxyindole (XII), m. 111-12°, λmaximum 3320 A. (log ε 4.49), λmin. 2720 A. (log ε 3.36); picrate, m. 201-3°. Similarly X with p-MeOC6H4NHNH2 gave 2-(4,5-diethyl-2-pyridyl)-3-ethyl-5-methoxyindole (XIII), b0.1 200-20°, m. 148°, λmaximum 3290 A. (log ε 4.43), λmin. 2730 A. (log ε 3.67); picrate, m. 225° (decomposition). Neither XII or XIII were identical with the degradation product from aricine (Goutarel, et al., C.A. 50, 5687g). The experimental process involved the reaction of 4-Bromo-5-ethyl-2-methylpyridine(cas: 98488-99-4).Recommanded Product: 98488-99-4

4-Bromo-5-ethyl-2-methylpyridine(cas:98488-99-4) belongs to pyridine-derivatives. Several pyridine derivatives play important roles in biological systems. While its biosynthesis is not fully understood, nicotinic acid (vitamin B3) occurs in some bacteria, fungi, and mammals.Recommanded Product: 98488-99-4

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Popp, Frank D.; McEwen, Wm. E. published an article in 1958, the title of the article was Approaches to the synthesis of emetine from Reissert compounds.Reference of 4-Bromo-5-ethyl-2-methylpyridine And the article contains the following content:

2-Methyl-4-nitro-5-ethylpyridine 1-oxide (94 g.) and 325 cc. PBr3 yielded by the method of Lee and Swan (C.A. 50, 13918g) 53% 2-methyl-4-bromo-5-ethylpyridine (I), b0.9 55-7°. EtBr added slowly with stirring to 36.48 g. Mg and 75 cc. dry Et2O, the mixture treated after the initial reaction had subsided with 108.5 g. I and 99.4 g. EtBr in 300 cc. dry Et2O at such a rate as to maintain gentle reflux, refluxed 2 hrs., the Et2O distilled, the residue diluted with 375 cc. dry C6H6, cooled, treated with 222.3 g. HC(OEt)3, refluxed 2 hrs., kept 15 hrs. at room temperature, treated with 500 cc. aqueous NH4Cl, the aqueous layer extracted with Et2O, the Et2O layer extracted with 1 l. N H2SO4 in portions, the acidic extract basified with aqueous NaHCO3, extracted with Et2O, and the extract worked up yielded 44.36 g. di-Et acetal (II) of 2-methyl-5-ethyl-4-pyridinecarboxaldehyde (III), b3 109-14°; picrate, m. 139-40° (EtOH) (all m.ps. are corrected). II (11.15 g.) in 90 cc. 10% HCl refluxed 2 hrs. under N, kept 16 hrs. at room temperature, basified with aqueous Na2CO3, extracted with CHCl3, and the extract worked up gave 6.57 g. III, b1 64-8°; oxime, m. 143-4° (EtOH). 3-Ethyl-4-methylpyridine was converted by the method of Berson and Cohen (C.A. 50, 9405i) to 69% 1-oxide (IV), b3 142-9°; picrate, m. 141.5-2.5° (EtOH). IV (186 g.) added slowly to 380 cc. warm Ac2O, refluxed 4 hrs., and evaporated gave 154 g. (3-ethyl-4-pyridyl)methanol acetate (V), b2.5 108-15°; picrate, m. 137-8° (EtOH). V (44.7 g.), 25 cc. 30% H2O2, and 115 g. glacial AcOH heated 4 hrs. on the steam bath, treated again with 21 cc. H2O2, heated 4 hrs., kept 36 hrs. at room temperature, evaporated in vacuo, the residue treated with 125 cc. Ac2O, heated 5.5 hrs. on the steam bath, concentrated in vacuo, treated with 175 cc. 6N HCl, refluxed 2 hrs., concentrated in vacuo, neutralized with aqueous NaOH, extracted with Et2O, and the extract worked up gave 10.2 g. 3-ethyl-4-pyridinecarboxaldehyde (VI), b2.5 71-5°; oxime, m. 146.5-8.5° (EtOH). VI (11.25 g.) and 52 cc. 13.5% alc. HBr kept 88 hrs. at room temperature, diluted with a large volume of C6H6, dried azeotropically during 24 hrs., evaporated, the residue basified with aqueous K2CO3, and the product isolated with Et2O gave 9.47 g. di-Et acetal (VIII) of VI, b1.9 100-2°; picrate, m. 115-16° (EtOH). 2-(p-Anisoyl)-6,7-dimethoxy-1,2-dihydroisoquinaldonitrile (VIII) (8.75 g.) in 45 cc. dry dioxane and 15 cc. dry Et2O treated at -20° under N slowly with stirring with PhLi (from 4.40 g. PhBr) in Et2O, then slowly with 3.38 g. VI, stirred 20 min. at -20° and 7 hrs. at room temperature, washed with H2O, 0.5N HCl, and H2O, distilled, and the gummy residue crystallized from EtOH gave 0.20 g. 6,7-dimethoxyisoquinaldonitrile (IX), m. 198.4-9.0° (EtOH); the HCl extract basified with aqueous NaOH, extracted with Et2O, the extract evaporated, and the gummy residue treated with EtOH gave 3.31 g. 1-(6,7-dimethoxyisoquinolyl)-4-(3-ethyl-4-pyridyl)carbinyl β-anisate (X), m. 248.2-8.7° (EtOH); the EtOH filtrate refluxed 2 hrs. with 2.8 g. KOH in 20 cc. H2O, the EtOH evaporated in vacuo, the aqueous residue extracted with Et2O, the precipitate filtered off, the extract evaporated, and the combined solids recrystallized from EtOH gave 1.57 g. 1-(6,7-dimethoxyisoquinolyl)-4-(3-ethyl-4-pyridyl)carbinol (XI), m. 168-9° (EtOH); the aqueous filtrate acidified gave 0.93 g. p-MeOC6H4CO2H. IX (0.02 g.) and 4.0 g. polyphosphoric acid heated 1 hr. on the steam bath, diluted with 10 cc. iced H2O, and neutralized with aqueous KOH gave 0.02 g. 6,7-dimethoxyisoquinaldamide, m. 169-70° (EtOH). 2-Benzoyl-6,7-dimethoxy-1,2-dihydroisoquinaldonitrile (1.45 g.) and 6 cc. SOCl2 heated 3 hrs. on the steam bath, evaporated in vacuo, the residue diluted with 35 cc. H2O, basified with aqueous NaOH, and the precipitate filtered off yielded 0.8 g. IX, m. 198.4-9.0° (EtOH). X (2.96 g.), 0.95 g. KOH, 25 cc. EtOH, and 55 cc. H2O refluxed 5 hrs., the EtOH evaporated in vacuo, and the aqueous residue filtered off gave 2.01 g. XI; the aqueous filtrate acidified gave 98% p-MeOC5H4CO2H. XI (0.5 g.), 0.5 g. Na2Cr2O7, and 10 cc. 80% AcOH stirred 1 hr. at room temperature, basified with aqueous NaHCO3, and extracted with CHCl3 gave 0.44 g. 1-(6,7-dimethoxyisoquinolyl) 3-ethyl-4-pyridyl ketone, m. 152-3° (ligroine). VIII (13.31 g.) in 70 cc. dry dioxane and 60 cc. dry Et2O treated under N at -25° slowly with stirring with PhLi from 6.60 g. PhBr in Et2O, then slowly with 5.70 g. III, stirred 1 hr. at -20°, kept 15 hrs. at room temperature, extracted with N HCl, washed, and the organic layer evaporated gave 4.06 g. IX; the HCl extract basified with aqueous NaOH, extracted with Et2O, the extract evaporated, the gummy residue (13.1 g.) dissolved in EtOH, the solution treated with 4.5 g. KOH in 30 cc. H2O, refluxed 1.5 hrs., the EtOH distilled, the aqueous distillation residue extracted with Et2O, and the extract worked up gave 3.95 g. 1-(6,7-dimethoxyisoquinolyl)(2-methyl-5-ethyl-4-pyridyl)carbinol, m. 174-5° (EtOH). 4-Pyridinecarboxaldehyde (XII) (50.0 g.) and 185 cc. 11.5% alc. HCl kept 90 hrs. at room temperature, diluted with 450 cc. dry C6H6, distilled with the azeotropic removal of the EtOH and H2O, the distillation residue basified with aqueous K2CO3, extracted with Et2O, and the extract worked up yielded 37.0 g. di-Et acetal (XIV) of XII, b6 99-100°. XIV (9.06 g.) and 9.25 g. Ph(CH2)2Br in 35 cc. dry xylene heated 1 hr. on the steam bath, the xylene solution decanted from a gummy precipitate, allowed to stand several days, diluted with a small amount of EtOH and a large amount of Et2O to precipitate more gum, and the combined precipitates crystallized from Et2O-EtOH gave 12.8 g. 1-phenethyl-4-(diethoxymethyl)pyridinium bromide (XV) dihydrate, m. 65.6-6.5°, which turned to a gum when dried over H2SO4 in vacuo; XV picrate, m. 104.6-5.6°. XV.2H2O (2.50 g.) in 25 cc. H2O treated with 8.8 g. K3Fe(CN)6 in 25 cc. H2O, kept overnight, diluted with 25 cc. C6H6, treated slowly with stirring at room temperature with 4.0 g. NaOH in 40 cc. H2O, stirred 1 hr., the aqueous layer extracted with C6H6, and the extract worked up gave 0.95 g. 1-phenethyl-4-(diethoxymethyl)-2(4H)-pyridone (XVI), m. 84.0-4.5°. 3,4-(MeO)2C6H3(CH2)2OH and PBr3 yielded 63% 3,4-(MeO)2C6H3(CH2)2Br (XVIII), b1.5 122-9°, m. 42-8°. XIV (3.62 g.) and 4.90 g. XVII heated 20 min. on the steam bath, kept overnight, and the gummy product treated with a small amount of EtOH and a large amount of Et2O yielded 4.90 g. 3,4-(MeO)2C6H3(CH2)2 analog (XVIII) of XV, m. 79-81.5°; picrate, m. 115.2-16.0° (EtOH). XVIII (2.83 g.) gave similarly 1.35 g. gummy product which, treated in EtOH, with a few drops of H2SO4, then with 2,4-(O2N)2C6H3NHNH2 solution, gave the 2,4-dinitrophenylhydrazone of 1-(3,4-dimethoxyphenethyl)-4-formyl-2(1H)-pyridone (XVIIIa), m. 270.0-70.8° (hot EtOH and hot Me2CO). VII (5.50 g.) and 6.44 g. XVII gave in the usual manner 90% 1-(3,4-dimethoxyphenethyl)-3-ethyl-4-(diethoxymethyl)pyridinium bromide (XIX), m. 140-1°; picrate, m. 126.3-7.1° (EtOH). XIX (4.54 g.) treated in the usual manner with K3Fe(CN)6 and the crude gummy product (2.90 g.) treated with EtOH, a few drops of H2SO4, and 2,4-(O2N)2C6H3NHNH2 solution yielded the 2,4-dinitrophenylhydrazone of the 3-Et derivative of XVIIIa, orange crystals, m. 268-9° (hot EtOH and hot Me2CO). 2-Methyl-5-ethyl-4-pyridinecarboxaldehyde di-Et acetal (3.41 g.) and 3.75 g. XVII yielded in the usual manner 43% 1-(3,4-dimethoxyphenethyl)-2-methyl-4-(diethoxymethyl)-5-ethylpyridinium bromide, m. 150.5-2.0° (Et2O-EtOH). The experimental process involved the reaction of 4-Bromo-5-ethyl-2-methylpyridine(cas: 98488-99-4).Reference of 4-Bromo-5-ethyl-2-methylpyridine

4-Bromo-5-ethyl-2-methylpyridine(cas:98488-99-4) belongs to pyridine-derivatives. Several pyridine derivatives play important roles in biological systems. While its biosynthesis is not fully understood, nicotinic acid (vitamin B3) occurs in some bacteria, fungi, and mammals.Reference of 4-Bromo-5-ethyl-2-methylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 14, 2003, Adam, Geo; Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas Johannes published a patent.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine The title of the patent was Preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for the treatment of neurological disorders. And the patent contained the following:

This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I; variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders, e.g. Alzheimer’s disease. Three examples of pharmaceutical compositions containing I are included. Ki values for 50 examples of I as metabotropic glutamate receptor antagonists are tabulated, e.g. 0.00135 μM for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preparations of I and many example preparations of intermediates are included. For example, 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol) by refluxing in xylene. For I: X is a single bond or an ethynediyl group; and wherein in case X is a single bond, R1 is H, cyano, halogen, lower alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl, or Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR’R”, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)m; m = 1-4; R’ is H, lower alkyl or C3-C6-cycloalkyl; R” is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or =N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH2)n-C(O)-OR”, -(CH2)n-C(O)-NR’R”, -(CH2)n-SO2-NR’R”, -(CH2)n-C(NH2):NR”, hydroxy, lower alkoxy, lower alkylthio, C3-C6-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR’R”, hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4. The experimental process involved the reaction of 4-Bromo-5-ethyl-2-methylpyridine(cas: 98488-99-4).Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

The Article related to alzheimer disease, anti-alzheimer agents, antipsychotics, biological memory retention defect, cognition enhancers, cognitive disorders, drug delivery systems, homo sapiens, human, metabotropic glutamate receptors role: bsu (biological study, unclassified), biol (biological study) (antagonists), nervous system agents, nervous system disease, psychosis, schizophrenia and other aspects.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 14, 2003, Adam, Geo; Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas Johannes published a patent.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine The title of the patent was Preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for the treatment of neurological disorders. And the patent contained the following:

This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I; variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders, e.g. Alzheimer’s disease. Three examples of pharmaceutical compositions containing I are included. Ki values for 50 examples of I as metabotropic glutamate receptor antagonists are tabulated, e.g. 0.00135 μM for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preparations of I and many example preparations of intermediates are included. For example, 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol) by refluxing in xylene. For I: X is a single bond or an ethynediyl group; and wherein in case X is a single bond, R1 is H, cyano, halogen, lower alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl, or Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR’R”, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)m; m = 1-4; R’ is H, lower alkyl or C3-C6-cycloalkyl; R” is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or =N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH2)n-C(O)-OR”, -(CH2)n-C(O)-NR’R”, -(CH2)n-SO2-NR’R”, -(CH2)n-C(NH2):NR”, hydroxy, lower alkoxy, lower alkylthio, C3-C6-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR’R”, hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4. The experimental process involved the reaction of 4-Bromo-5-ethyl-2-methylpyridine(cas: 98488-99-4).Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

The Article related to alzheimer disease, anti-alzheimer agents, antipsychotics, biological memory retention defect, cognition enhancers, cognitive disorders, drug delivery systems, homo sapiens, human, metabotropic glutamate receptors role: bsu (biological study, unclassified), biol (biological study) (antagonists), nervous system agents, nervous system disease, psychosis, schizophrenia and other aspects.Application In Synthesis of 4-Bromo-5-ethyl-2-methylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem